Developing Peptides for Hypoparathyroidism and Other Rare Endocrine and Metabolic Disorders with Thierry Abribat Amolyt Pharma TRANSCRIPT
Download PDFJun 29, 2020
Thierry Abribat, Founder and CEO, Amolyt Pharma is developing a portfolio of products of peptides for rare endocrine and metabolic disorders. Their first project is a peptide hormone that is a parathyroid hormone being developed to treat hypoparathyroidism, a condition most often suffered by middle aged women and...
Jun 29, 2020
Thierry Abribat, Founder and CEO, Amolyt Pharma is developing a portfolio of products of peptides for rare endocrine and metabolic disorders. Their first project is a peptide hormone that is a parathyroid hormone being developed to treat hypoparathyroidism, a condition most often suffered by middle aged women and...
Raising Awareness About Barth Syndrome and Other Rare Diseases With Maria Picone TREND.community and Shelley Bowen Barth Syndrome Foundation TRANSCRIPT
Download PDFApr 20, 2020
Maria Picone, Founder, TREND.community and Shelley Bowen, Founder and Director, Barth Syndrome Foundation explain the challenges doctors face in diagnosing a rare disease like Barth Syndrome, the need to educate doctors about symptoms and warning signs of rare diseases, the need for genetic testing to further inform...
Apr 20, 2020
Maria Picone, Founder, TREND.community and Shelley Bowen, Founder and Director, Barth Syndrome Foundation explain the challenges doctors face in diagnosing a rare disease like Barth Syndrome, the need to educate doctors about symptoms and warning signs of rare diseases, the need for genetic testing to further inform...
Gene Therapies Target Rare Pediatric Diseases with Kinnari Patel Rocket Pharmceuticals TRANSCRIPT
Download PDFFeb 25, 2020
Kinnari Patel, Chief Operating Officer, Rocket Pharmaceuticals discusses how Rocket is focused on creating new options for patients contending with rare genetic diseases. Rocket is advancing several gene therapies for rare pediatric diseases and Kinnari provides insights into how the company is tackling the unique...